RxDoctor Payments Data

Amy Thomas, MD

Family Medicine · San Antonio, TXNPI 1497739882

Payments from drug & device makers

$12,208in general payments, 2019–2025

Across 623 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Boehringer Ingelheim$957
  • Pfizer$534
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$12,185100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,208 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$40,132
Medicare patients
62
Services billed
548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$18,563
JardianceEmpagliflozin12$18,302
MounjaroTirzepatide17$16,890
FarxigaDapagliflozin Propanediol11$5,664
Rosuvastatin Calcium100$1,050
Levothyroxine Sodium57$620
Estradiol14$520
Bupropion XlBupropion Hcl23$436
Escitalopram Oxalate28$406
Ropinirole Hcl12$367
Ibandronate Sodium26$315
Clonazepam15$301
Gabapentin26$263
Losartan Potassium14$262
Ondansetron OdtOndansetron12$207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,556$18,56317 claims
Boehringer IngelheimJardiance$957$18,30212 claims
Lilly USA, LLCMounjaro$1,512$16,89017 claims
AstraZenecaFarxiga$1,600$5,66411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →